Thursday, November 16, 2017 2:16:01 PM
"Goldman Sachs Group Inc. lifted its holdings in Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) by 323.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 62,977 shares of the biotechnology company’s stock after acquiring an additional 48,090 shares during the quarter. Goldman Sachs Group Inc. owned 0.21% of Conatus Pharmaceuticals worth $363,000 as of its most recent SEC filing."
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM